Polyzois Makras
Overview
Explore the profile of Polyzois Makras including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
1490
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anastasilakis A, Makras P, Polyzos S, Kumar A, Kalra B, Mantzoros C
Diabetes Obes Metab
. 2025 Jan;
27(4):2288-2293.
PMID: 39844694
No abstract available.
2.
Makras P, Erickson D, Davidge-Pitts C, Diamond E, Allen C, McClain K, et al.
J Clin Endocrinol Metab
. 2024 Dec;
PMID: 39699236
Endocrinopathies are frequently the initial presentation of histiocytic neoplasms, which are rare hematologic disorders affecting multiple organ systems. Langerhans cell histiocytosis and Erdheim-Chester disease are 2 such disorders known to...
3.
Kokotas S, Budowle B, Papatheodorou A, Bolanaki E, Kondili A, Metheniti A, et al.
Forensic Sci Int Genet
. 2024 Sep;
74:103131.
PMID: 39241298
A pilot study was performed using two different DNA technology platforms conducted by two laboratories to analyze DNA extracted from 83-year-old, human male skeletal remains from 16 individuals, of which...
4.
Palermo A, Tabacco G, Makras P, Zavatta G, Trimboli P, Castellano E, et al.
Rev Endocr Metab Disord
. 2024 Aug;
25(5):875-896.
PMID: 39162944
Primary hyperparathyroidism (PHPT) is a common endocrine disease characterized by hypercalcemia due to inappropriately high parathyroid hormone secretion. While in the typical, symptomatic form of the disease diagnosis is set...
5.
Anastasilakis A, Polyzos S, Makras P, Savvidis M, Mantzoros C
J Bone Miner Res
. 2024 Jul;
39(9):1306-1314.
PMID: 38976019
The activins-follistatins-inhibins (AFI) hormonal system affects bone metabolism. Treatments that alter bone metabolism may also alter the AFI molecules. In this non-randomized, open-label, head-to-head comparative study, circulating levels of the...
6.
Anastasilakis A, Yavropoulou M, Palermo A, Makras P, Paccou J, Tabacco G, et al.
Eur J Endocrinol
. 2024 Jun;
191(1):R9-R21.
PMID: 38938063
Osteoanabolic agents are used as a first line treatment in patients at high fracture risk. The PTH receptor 1 (PTH1R) agonists teriparatide (TPTD) and abaloparatide (ABL) increase bone formation, bone...
7.
Makras P, Yavropoulou M, Anastasilakis A, Papatheodorou A, Tekedis C, Papapoulos S
Osteoporos Int
. 2023 Dec;
35(4):741-743.
PMID: 38147135
No abstract available.
8.
Yavropoulou M, Kasdagli M, Makras P, Diomatari K, Anastasilakis A, Mitsikostas D, et al.
Maturitas
. 2023 Nov;
179:107874.
PMID: 37976923
Objective: Nocebo is a concept of therapeutics referring to unpleasant symptoms attributed by a patient to a drug, due to negative anticipation. Patients receiving oral anti-osteoporotic drugs in randomized controlled...
9.
Makras P, Yavropoulou M, Polyzos S, Papapoulos S, Georgakopoulou D, Papatheodorou A, et al.
Osteoporos Int
. 2023 Oct;
35(2):365-370.
PMID: 37783758
Purpose: In women with postmenopausal osteoporosis the aetiology of the observed inverse relationship between duration of denosumab (Dmab) therapy and bone loss after its discontinuation is currently unknown. In studies...
10.
Anastasilakis A, Makras P, Paccou J, Bisbinas I, Polyzos S, Papapoulos S
J Clin Med
. 2023 Sep;
12(18).
PMID: 37762815
Rebound-associated vertebral fractures (RVFx) following denosumab discontinuation are typically multiple, are commonly associated with acute sharp pain, increase the risk of imminent fractures, and are pathogenetically different from common osteoporotic...